Invicta Diagnostic Ltd
Peer comparison
| Company | Price↕ | Market Cap↕ | P/E↕ | P/B↕ | ROE %↕ | ROCE %↕ | Div yield %↕ | Valuation |
|---|---|---|---|---|---|---|---|---|
| Dr. Lal Path Labs Ltd. | ₹ 1,897.00 | ₹ 31,676 Cr | 58.46 | 12.63 | 22.30 | 28.00 | 0.83 | Above FV |
| Vijaya Diagnostic Cen Ltd | ₹ 1,502.10 | ₹ 15,471 Cr | 82.67 | 16.14 | 18.30 | 20.50 | 0.00 | Above FV |
| Metropolis Healthcare Ltd | ₹ 583.00 | ₹ 12,095 Cr | 59.61 | 7.99 | 13.60 | 17.80 | 0.00 | Above FV |
| Thyrocare Tech Ltd | ₹ 552.70 | ₹ 8,797 Cr | 50.02 | 15.02 | 28.40 | 35.40 | 0.00 | Above FV |
| Nephrocare Health Serv L | ₹ 766.25 | ₹ 7,705 Cr | 90.15 | 6.89 | 8.83 | 15.30 | 0.00 | Above FV |
| Krsnaa Diagnostics Ltd | ₹ 552.90 | ₹ 1,794 Cr | 18.65 | 1.83 | 10.90 | 12.70 | 0.00 | Above FV |
| Suraksha Diagnostic Ltd | ₹ 325.00 | ₹ 1,693 Cr | 47.10 | 6.89 | 14.20 | 17.30 | 0.00 | Above FV |
| 3B Blackbio Dx Ltd. | ₹ 1,420.00 | ₹ 1,219 Cr | 21.41 | 3.66 | 19.80 | 25.50 | 0.00 | Above FV |
| Health X Platform Limited | ₹ 306.95 | ₹ 976 Cr | — | 1.52 | 0.29 | -0.05 | 0.00 | Above FV |
| Gaudium Ivf N Women H L | ₹ 118.10 | ₹ 860 Cr | 37.02 | 4.84 | 24.70 | 29.30 | 0.00 | Above FV |
| Chandan Healthcare Ltd | — | ₹ 489 Cr | 18.60 | 2.11 | 13.20 | 23.10 | 0.00 | — |
| Invicta Diagnostic Ltd | — | ₹ 86 Cr | 19.20 | 1.89 | 14.00 | 19.40 | 0.00 | — |
Price, market cap, P/E, P/B and dividend yield reflect the live quote (delayed, cached 15 min); ROE/ROCE from reported financials. The highlighted row is the current company. Click a column header to sort. Educational data only.
How to read the peer comparison
This table places the company beside others in the same industry on a few common measures. Comparison adds context that a single company's numbers cannot give on their own.
- Valuation multiples like P/E and P/B are most meaningful within the same industry, because different industries naturally trade at different levels. Comparing a company only to its peers is more useful than to the whole market.
- Return measures (ROE, ROCE) show how efficiently each company turns capital into profit. A company well ahead of or behind its peers here is worth understanding.
- No single column decides anything. A beginner reads the row across — valuation, returns, and size together — and treats the highlighted current company as one data point among its peers.
- Use the sortable headers to rank peers on any measure, but remember that "cheaper" or "higher" on one metric is a starting question, not an answer.
Educational only — not a recommendation to buy, sell, or hold any security.